Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079062 | 0.80 | CNR2 (0.47) | CNR2 | |
| SCHEMBL5521745 | 0.76 | PDE3B (0.35) | CNR2PDE3BPDE3AHPGDALDH1A1 | |
| SCHEMBL14611166 | 0.76 | PDE3B (0.42) | PDE3BPDE3AHPGDALDH1A1LMNA | |
| SCHEMBL13948583 | 0.74 | HPGD (0.43) | PDE3BPDE3AHPGDALDH1A1LMNA | |
| SCHEMBL620000 | 0.73 | HTT (0.50) | PDE3BPDE3AHPGDALDH1A1LMNA | |
| SCHEMBL3926846 | 0.72 | HTT (0.42) | PDE3BPDE3AHPGDALDH1A1LMNA | |
| SCHEMBL1267116 | 0.71 | ALDH1A1 (0.54) | PDE3BPDE3AHPGDALDH1A1LMNA | |
| SCHEMBL5749110 | 0.71 | HTT (0.40) | PDE3BPDE3AHPGDALDH1A1LMNA | |
| SCHEMBL14610702 | 0.70 | SLC6A4 (0.39) | CNR2PDE3BPDE3AALDH1A1LMNA | |
| SCHEMBL21972302 | 0.69 | POLB (0.40) | PDE3BPDE3AHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | CNR2 4489/4885SCN9A 2595/4885PDE3B 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.